结节病患者流感疫苗接种的免疫效果与安全性:SARCOVAC研究
SARCOVAC是一项开放标签、多中心、前瞻性临床试验,2012-2013年纳入83例结节病患者和99名健康对照,评估三价灭活流感疫苗的免疫效果与安全性。结果显示,患者对A/H1N1和A/H3N2株的血清转化率高于对照,B株无差异;疫苗未显著影响结节病病程,反应原性无差异。结论支持对结节病患者推荐流感疫苗接种。
要点
- 结节病患者接种流感疫苗后A/H1N1和A/H3N2血清转化率高于健康对照。
- 疫苗接种未显著影响结节病病程,反应原性与健康对照无差异。
- 结果支持对结节病患者(包括重症和免疫抑制治疗者)推荐流感疫苗接种。
核心结论
- 流感疫苗对结节病患者具有免疫原性,包括重症和接受免疫抑制治疗者。
- 结果支持对结节病患者推荐流感疫苗接种,因其是严重感染高危人群。
研究设计与样本
- SARCOVAC为开放标签、多中心、前瞻性临床试验,于2012-2013年开展流感疫苗接种。
- 共招募191名参与者,182名(83例结节病患者、99名健康对照)纳入分析。
- 主要结局为比较第21天患者与对照对各病毒株的血清转化率。
主要发现
- 第21天,患者A/H1N1株血清转化率为62.2%,对照为45.4%(p=0.025)。
- 第21天,患者A/H3N2株血清转化率为58.5%,对照为35.1%(p=0.002)。
- 第21天,B株血清转化率患者为72%,对照为60.8%(p=0.118),无统计学差异。
- 第21天血清保护率范围为73.2%至90.7%,第180天为59.4%至79.4%,患者与对照间无统计学差异。
- 疫苗接种未显著影响结节病病程,患者与健康对照的反应原性无差异。
临床怎么用
- 对结节病患者,包括重症和接受免疫抑制治疗者,可依据结果推荐接种流感疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Half of patients with sarcoidosis have significant organ involvement and require long-lasting immunosuppressive treatment. We aimed to evaluate safety and immunological efficacy of a trivalent inactivated influenza vaccine in patients with sarcoidosis compared with healthy controls. METHODS: The SARCOVAC trial was an open-label, multicenter, prospective clinical trial. Influenza vaccination was performed in 2012-2013 in patients with both sarcoidosis and an indication for influenza vaccination, and in healthy controls. Antibody titers against A/H1N1, A/H3N2, and B influenza virus antigens were measured immediately before and 21 and 180 days after vaccination. The primary outcome was the comparison of seroconversion rates for each viral strain at day 21 between patients and controls. FINDINGS: We recruited 191 participants among whom 182 (83 patients, 99 controls) were included in the analysis. At D21, seroconversion rates were higher in patients than in controls for A/H1N1 strain (62.2% versus 45.4%, p = 0.025), and A/H3N2 strain (58.5% versus 35.1%, p = 0.002) but did not differ for B strain (72% versus 60.8%, p = 0.118). Seroprotection rates ranged between 73.2% and 90.7% at D21 and 59.4% and 79.4% at day 180 in patients and controls, respectively, with no statistical difference. The vaccination did not significantly impact the course of sarcoidosis. No difference in reactogenicity was found between patients and healthy controls. INTERPRETATION: Influenza vaccination is immunogenic in patients with sarcoidosis, including those with severe disease and immunosuppressive therapy. These results support the recommendations for influenza vaccination in patients with sarcoidosis who are at high risk of severe infections.
引用
- Ranque B, Galtier F, Nunes H, et al. Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study. Vaccine. 2026. PMID: 42167137. doi:10.1016/j.vaccine.2026.128732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。